News
1d
News-Medical.Net on MSNMicrobial signals rewire immunity in esophageal squamous cell carcinomaEsophageal squamous cell carcinoma (ESCC) is a deadly cancer with particularly high prevalence in East Asia. While ...
Discover how gut and oral bacteria influence immune evasion in esophageal cancer, impacting treatment response and disease ...
The effects of F. nucleatum, PLA, and CLEC12A on macrophages. GA, UNITED STATES, July 19, 2025 /EINPresswire / -- A growing body of researc ...
Researchers from the University of Turku and Turku University Hospital, Finland, led by Docent Sami Ventelä and Professor ...
Results from the Phase III KEYNOTE-689 trial show that adding perioperative Keytruda (pembrolizumab) to standard-of-care ...
Purpose To provide evidence-based recommendations for the use of transoral robotic surgery (TORS) in the multidisciplinary management of oropharyngeal squamous cell cancer (OPC).
(NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved TEVIMBRA ® (tislelizumab), in combination with gemcitabine and cisplatin, ...
Panelists discuss how treatment selection between combination immunotherapy (IO) and chemotherapy alone should favor the FDA-approved carboplatin-paclitaxel-retifanlimab regimen for most patients with ...
Fibrolamellar hepatocellular carcinoma (FLC) has no approved treatment and occurs mostly in adolescents and young adults - KUALA LUMPUR, Malaysia, July 07, 2025 (GLOBE NEWSWIRE) -- Cyclacel ...
InnoCare Pharma gets China NMPA approval to conduct clinical trial for a novel ADC ICP-B794 in China
InnoCare Pharma gets China NMPA approval to conduct clinical trial for a novel ADC ICP-B794 in China: Beijing Saturday, July 5, 2025, 11:00 Hrs [IST] InnoCare Pharma, a commercial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results